赛诺菲此次出手的DR-0201，是一款 潜在同类首创靶向CD20的双抗 ，可作用于特定的组织驻留和运输髓系细胞，通过靶向吞噬作用诱导深度B细胞耗竭， 可用于治疗肿瘤和自免疾病， ...

智通财经APP获悉，3月20日，赛诺菲(SNY.US)宣布，已与临床阶段生物制药公司Dren Bio达成最终协议，收购髓系细胞双抗DR-0201，交易总金额为19亿美元，其中首付款6亿美元，预计在2025年第二季度完成。根据协议条款，赛诺菲将通过收购 ...

3月20日，赛诺菲宣布，已与临床阶段生物制药公司Dren Bio达成最终协议，收购髓系细胞双抗DR-0201，交易总金额为19亿美元，预计在2025年第二季度完成。 根据协议条款，赛诺菲将通过收购Dren ...

2024年3月20日，赛诺菲公司宣布与临床阶段的生物制药企业Dren Bio签署了最终收购协议，收购该公司开发的髓系细胞靶向双特异性抗体DR-0201，总交易额达到19亿美元，其中首期付款为6亿美元，预计收购将在2025年第二季度完成。

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...

Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Sanofi SA is getting deeper into oncology and immunology therapy development through buying Dren Bio Inc.’s myeloid cell engager for deep B-cell depletion, DR-0201. The deal could reach as high as $1.